Arcus Biosciences Files 2025 Proxy Statement on Executive Pay
Ticker: RCUS · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 1724521
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Arcus exec pay details out, shareholders get the scoop.
AI Summary
Arcus Biosciences, Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted and outstanding, as well as details on the company's compensation policies and practices. Arcus Biosciences is a biotechnology company focused on developing novel cancer therapies.
Why It Matters
This filing provides shareholders with crucial information regarding how Arcus Biosciences compensates its top executives, impacting investor decisions and corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing executive compensation and is not indicative of immediate financial risk.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Filer of the DEF 14A
- 20250422 (date) — Filing date of the DEF 14A
- 20250610 (date) — Period of report
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide shareholders with information regarding Arcus Biosciences, Inc.'s executive compensation, director compensation, and other corporate governance matters, as required by the Securities and Exchange Commission.
When was this DEF 14A filed?
This DEF 14A filing was filed on April 22, 2025.
What fiscal year does the compensation information primarily cover?
The compensation information primarily covers the fiscal year ending December 31, 2024.
What is Arcus Biosciences, Inc.'s Standard Industrial Classification (SIC) code?
Arcus Biosciences, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Arcus Biosciences, Inc. headquartered?
Arcus Biosciences, Inc. is headquartered at 3928 Point Eden Way, Hayward, CA 94545.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 regarding Arcus Biosciences, Inc. (RCUS).